A Agilent Technologies Inc.

Agilent Collaborates with METTLER TOLEDO to Reduce Errors in Sample Preparation Workflows for Better Chromatographic Results

(NYSE: A) today announced that it is collaborating with METTLER TOLEDO to address one of the biggest concerns in any laboratory—error-prone sample preparation. This integrated solution allows the automatic and seamless transfer of weighing results and the associated metadata from METTLER TOLEDO LabX™ Balance software to Agilent OpenLab software.

Sample preparation is a critical part of many laboratory workflows. It is a time-consuming bottleneck and a frequent source of errors and inaccuracies that often leads to costly quality investigations or rework. This solution from Agilent and METTLER TOLEDO, launched in Munich at Analytica 2022 in June, offers a fully automated and digitalized LC or GC workflow designed to eliminate common errors in the weighing process.

The complete solution automatically transfers weighing results to the latest release of Sample Scheduler for Agilent OpenLab CDS. Sample Scheduler retrieves the sample and weight data from the METTLER TOLEDO LabX software and allows users to seamlessly route sample and weighing information to any instrument in the laboratory.

“We are pleased to announce this collaboration with METTLER TOLEDO,” said Jacob Thaysen, president, Agilent's Life Sciences and Applied Markets Group. He added, “This new sample preparation workflow not only improves results, but it also offers a truly digital user experience for operating chromatographic instruments—helping our customers build their labs of the future.”

“This is a prime example of how two prevalent vendors of lab equipment have collaborated to address one of the biggest concerns in the laboratory,” said Patrick Kaltenbach, CEO of METTLER TOLEDO. “The seamless integration of balances and chromatography instruments in a digital and automated sample preparation and analysis process allows a drastic reduction or even elimination of transcription and calculation errors, significantly increasing lab productivity.”

By addressing one of the biggest, most basic laboratory challenges—transferring weighing results accurately to other lab systems—the Agilent/METTLER TOLEDO solution will accelerate the digital transformation of laboratories.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on , , and .

EN
01/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch